<DOC>
	<DOCNO>NCT00523341</DOCNO>
	<brief_summary>The primary objective describe safety tolerability 10 year 7 year denosumab administration measure adverse event monitoring , immunogenicity safety laboratory parameter participants previously receive denosumab placebo , respectively .</brief_summary>
	<brief_title>Extension Study Evaluate Long Term Safety Efficacy Denosumab Treatment Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Postmenopausal woman attend 20030216 ( NCT00089791 ) study month 36 visit eligible participate meet inclusion exclusion criterion give . Inclusion Criteria Subjects must sign informed consent study specific procedure perform agree receive denosumab 60 mg subcutaneous injection every 6 month Subjects must discontinue investigational product 20030216 study must attend 20030216 study month 36 visit Subjects must reconsented prior ( ) 24 month visit participation beyond month 24 . Exclusion Criteria Permanently nonambulatory subject ( use assistive device eg , cane , walker , etc . permit ) Missed 2 investigational product dose 20030216 study Any disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply study procedure Developed sensitivity mammalian cell derive drug product 20030216 study Unable tolerate calcium supplementation last 6 month participation 20030216 study ( month 30 month 36 20030216 study visit ) Currently receive investigational product denosumab receive investigational product 20030216 study Current use follow osteoporosis agent : bisphosphonates , calcitonin , fluoride , parathyroid hormone , selective estrogen receptor modulators , systemic oral transdermal estrogen ( except vaginal preparation estrogen cream acceptable ) , strontium , tibolone For bone biopsy substudy subject : know suspected sensitivity contraindication tetracycline derivative</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>94 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>postmenopausal osteoporosis</keyword>
	<keyword>low bone density</keyword>
	<keyword>fracture</keyword>
	<keyword>low bone mass</keyword>
</DOC>